Abiomed Receives 510(k) Clearance from FDA for Impella 2.5 Device

Abiomed Announces Results of Impella(R) 2.5 FDA PROTECT I Safety Trial for High-Risk PCI Cases

Abiomed Announces Schedule for TCT 2007 Global Live Broadcasts of Impella(R) 2.5 Patient Procedures

Abiomed Announces Update on Impella(R) 2.5 510(k) Process

Abiomed Receives Conditional FDA Approval for Impella 2.5 Pivotal Study at up to 150 Hospitals

Abiomed Announces Canadian Regulatory Approvals of Impella Circulatory Support Technologies

Abiomed Announces Schedule of Events for Breakthrough Impella Technology at EuroPCR Conference in Barcelona

Abiomed Completes Enrollment of Pilot Clinical Trial for Impella 2.5 Circulatory Support System

Abiomed's Impella 2.5 Circulatory Support System Receives Medical Design Excellence Award

Abiomed Expands Availability of Impella Circulatory Support Technologies with Regulatory Approvals in India

Abiomed Announces Data on Impella 2.5 for Improved Cardiac Function for Pre-Shock Acute Myocardial Infarction

Abiomed to Showcase Impella 2.5 Advanced Circulatory Support Technologies at American College of Cardiology's Annual Scientific Sessions

The Impella® is an Investigational Device limited by U.S. Federal Law solely for Investigational Use in the United States.